TABLE 8.

Clinical trials with mirvetuximab soravtansine in ovarian cancer.

Name of the study	Year of the study	Phase of the study	Research group	Dose of mirvetuximab soravtansine	Results
IMGN853 (Moore et al., 2017)	2017	I	44	Doses escalating from 0.15 to 7.0 mg/kg, once every 3 weeks	2 patients with epithelial ovarian cancer achieved confirmed tumor responses, according to Response Evaluation Criteria in Solid Tumors 1.1 - partial response
FORWARD II (O Malley et al., 2020)	2020	Ib	66	6 mg/kg, once every 3 weeks	PFS 6.9 months, ORR 39% (including 5 complete responses and 21 partial responses)
SORAYA (Matulonis et al., 2023)	2023	II	106	6 mg/kg, once every 3 weeks	PFS 4.3 months, OS 13.8
FORWARD I (Moore et al., 2021)	2021	III	352, (mirvetuximab soravtansine group n = 243, chemotherapy group n = 109)	6 mg/kg, once every 3 weeks	Mirvetuximab soravtansine group, chemotherapy group: PFS 4.8, 3.3 months, respectively

PFS, progression-free survival; ORR, objective response rate; OS, overall survival.